Ugrás a tartalomra
Merck

CLLS1045

Sigma-Aldrich

MCF10A CELLS HER2 (-/-)

human female maMilliporeary glands (Source Disease: Fibrocystic Disease)

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

UNSPSC kód:
41106514
eCl@ss:
32190102
NACRES:
NA.81
biológiai forrás:
human female mammary glands (Source Disease: Fibrocystic Disease)

Terméknév

MCF10A CELLS HER2 (-/-),

biológiai forrás

human female mammary glands (Source Disease: Fibrocystic Disease)

Minőségi szint

OMIM elérési szám

tárolási hőmérséklet

−196°C

Géninformáció

Általános leírás

MCF10A CELLS HER2 (-/-) are pre-neoplastic mammary epithelial cells from a human adult female with a ZFN knock out modification.
This cell line corresponds to ATCC Catalog No. CRL-10317.

Alkalmazás

Cell freezing medium-DMSO 1X, Cat. No. C6164
Media renewal changes two to three times per week.
Rapidly thaw vial by gentle agitation in 37°C water bath (~2 minutes), keeping vial cap out of the water. Decontaminate with 70% ethanol, add 9 mL culture media and centrifuge 125 x g (5-7 minutes). Resuspend in complete culture media and incubate at 37°
The base medium for this cell line is Dulbecco′s Modified Eagle′s Medium/Ham′s Nutrient Mixture F-12, Cat. No. 51448C. To make the complete growth medium, add the following components to the base medium: horse serum, Cat No. H1270, to a final concentration (v/v) of 5%; cholera toxin, Cat No. C8052, to a final concentration of 1 ng/mL; human insulin, Cat No. I9278, to a final concentration of 10 ug/mL; epidermal growth factor, Cat No. E9644, to a final concentration of 10 ng/mL; and hydrocortisone, Cat No. H6909, to a final concentration of 0.5 ug/mL.

Biokémiai/fiziológiai hatások

Human epidermal growth factor receptor 2 (HER2) signaling pathway stimulates cell proliferation and survival in the majority of breast cancers. Thus, overexpression of this protein causes breast cancer. Heterodimeric complex of HER2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the PI3K/AKT anti-apoptosis pathway. Increased expression of HER2 is also observed in ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of HER2. This domain is missing in p95, a truncated form of HER2, and hence these cancer cells show resistance to trastuzumab. HER2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers.

Tulajdonságok és előnyök

These MCF10A cells are adherent with a doubling time of approx. 20 hours
Zinc finger nuclease (ZFN) knockout on chromosome 17q21.1

Minőség

Tested for Mycoplasma, sterility, post-freeze viability, short terminal repeat (STR) analysis for cell line identification, cytochrome oxidase I (COI) analysis for cell line species confirmation.

Jogi nyilatkozat

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Kit Components Also Available Separately

Product No.
Leírás
Biztonsági adatlap

  • MCF10A CONTROL CELLS 1 vial

  • MCF10A CELLS HER2 (-/-) 1 vial

Tárolási osztály kódja

10 - Combustible liquids

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable


Válasszon a legfrissebb verziók közül:

Analitikai tanúsítványok (COA)

Lot/Batch Number

Sajnos jelenleg COA nem áll rendelkezésre ehhez a termékhez online.

Ha segítségre van szüksége, lépjen velünk kapcsolatba Vevőszolgálat

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21(2), 382-389 (2016)
HER2: biology, detection, and clinical implications.
Gutierrez C and Schiff R.
Archives of Pathology & Laboratory Medicine, 135(1), 55-62 (2011)
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP, et al.
Molecular Diagnosis & Therapy, 17(2), 85-99 (2013)

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással